Stifel cut its price target for Candel Therapeutics from $22 to $19 but still rates it a Buy.

Nov 13, 2026, 9:24 AM ETOpinionRead the original at marketscreener.com

Neutral

Stifel cut its price target from $22 to $19 but kept its Buy rating, leaving its view mixed. The report gives no new company results or clinical details.

CADL · Candel Therapeutics

AI read · Neutral

The AI's read

The lower target shows Stifel now sees less value in the shares than before. Keeping its Buy rating points the other way. This update gives no details about changed results or clinical programs, so it does not support a clear change in Candel's outlook.

Get alerts for CADL

Follow Candel Therapeutics (CADL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CADL

Free on the App Store and Google Play, or on the web.